PPIB and Alzheimer disease: Moreover, treatments with β- and γ-secretase inhibitors were able to significantly reduce amyloid and tau pathology in AD-like brain organoids [103, 104], suggesting the potential of utilizing these organoids as platforms for preclinical drug discovery in AD.